Form 6-K



FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

 
For the month ended
  
 
Commission File Number
  
 
October 2007
  
1-32608
  

 
VIREXX MEDICAL CORP.
  
 
(Translation of registrant's name into English)
  
 
8223 Roper Road NW, Edmonton, Alberta, Canada T6E 6S4
  
 
(Address of principal executive offices)
  

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F X Form 40-F .....

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ..... No ..X..

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ________






EXHIBIT LIST

Exhibit
 
Description
99.1
 
Press Release Announcing Second Ovarex® MAb Phase III Trial Reaches 118th Relapse Event
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
VIREXX MEDICAL CORP. 
 
 
 
 
 
 
Date:  October 16, 2007
By:  
   /s/  Brent Johnston
 
 
Brent Johnston
Controller